On March 29, 2018, KalGene Pharmaceuticals Inc. announced that it had completed its second tranche of Series A financing, raising $1.67 million. The round was led by Merck Lumira Biosciences Fund, L.P. and Merck Lumira Biosciences Fund (Québec), L.P.
KalGene Pharmaceuticals is a Canadian biotechnology company. It plans to use the funding to support the development of its leading therapeutic medicine for the treatment of Alzheimer’s disease.
Osler, Hoskin & Harcourt LLP represented KalGene Pharmaceuticals with a team consisting of Nathalie Beauregard and Tim Apedaile (Corporate).